Royalty Pharma (RPRX) Liabilities and Shareholders Equity (2019 - 2026)

Royalty Pharma has disclosed Liabilities and Shareholders Equity across 8 years of filings, most recently posting $19.8 billion for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 8.17% year-over-year to $19.8 billion; the TTM figure through Jun 2026 stood at $78.6 billion (up 8.87% YoY), while the FY2025 annual figure was $19.6 billion, up 7.67% from the prior year.
• Liabilities and Shareholders Equity came in at $19.8 billion for Q2 2026 at Royalty Pharma, roughly flat from $19.8 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $19.8 billion in Q2 2026 to a low of $15.9 billion in Q3 2023.
• Average Liabilities and Shareholders Equity over 5 years is $17.8 billion, with a median of $17.7 billion recorded in 2022.
• Year-over-year, Liabilities and Shareholders Equity fell 10.28% in 2023 and grew 13.79% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $16.8 billion in 2022, then slipped by 2.57% to $16.4 billion in 2023, then rose by 11.24% to $18.2 billion in 2024, then climbed by 7.67% to $19.6 billion in 2025, then increased by 1.01% to $19.8 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $19.8 billion in Q2 2026, $19.8 billion in Q1 2026, and $19.6 billion in Q4 2025.